Rate of discontinuation and reasons for discontinuation of intravesical onabotulinum toxin A treatment in patients with symptomatic Overactive Bladder (OAB)

• G. Scrimgeour,
• K. Aleksejeva,
• R. Axell,
• H. Yasmin,
• M. Nadeem,
• M.H. Pakzad,
• R. Hamid,
• J.L. Ockrim,
• T.J. Greenwell

Affiliations

G. Scrimgeour

K. Aleksejeva

R. Axell

H. Yasmin

M. Nadeem

M.H. Pakzad

R. Hamid

J.L. Ockrim

T.J. Greenwell